kidney care come
at a molecular level.
Customized care can improve health
outcomes — but it requires deeper insights. That’s where Natera comes in. With Natera’s precise DNA analysis, you can effectively manage and provide the best available care to all your kidney patients.LEARN MORE
From early findings through post-renal transplant, Natera has you covered with more accurate results and better post-transplant care.
diagnosis of chronic kidney disease.
for better patient care. Up to 36% of all adult-onset cases have
an undiagnosed cause.1 Testing at the molecular level offers deeper insights. See a recent publication highlighting 6 key elements necessary for incorporating genetic testing into your clinical practice.VIEW THE STUDY
With Renasight. Leverage next-gen sequencing on 380+ genes linked to CKD.Molecular testing offers thorough data, which allows for more individualized patient care.DOWNLOAD BROCHURE
post-transplant assessments?
post-transplant rejection assessments by more than 50%.3In a recently published clinical validation study, donor-derived cell-free DNA was more reliable than serum creatinine in identifying all types of rejection.VIEW THE STUDY
transplant rejection with great precision.
Genetic testing can guide us to help improve patient care and outcomes. I encourage you to utilize the Renasight test for your patients, I have been surprised and interested in the results I've been seeing.”
Having the Prospera test and its reliability makes me more confident that when I’m taking care of the patient, I’m making better decisions.”
ProReach allows for patients to get their Prospera test and their complete transplant profile at the same time—including their drug levels, serum creatinine, and other routine tests.”
2. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.
3. Peabody, et al. Randomized clinical utility trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal post-transplant patients. International Urology and Nephrology. 2020;
doi.org/10.1007/s11255-020-02491-1.
4. Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.
In the Prospera early access program, Natera has received tests from 45% of the top 50 and 37% of the top 100 transplant centers by volume
Second line
Natera May 4, 2020 Press Release